Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(40%)
Results Posted
150%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (80.0%)
N/A1 (20.0%)

Trials by Status

completed240%
active_not_recruiting120%
recruiting120%
terminated120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

NCT06639854
active_not_recruitingphase_2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

NCT05907746
completedphase_2

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
completedphase_2

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

NCT02639559
terminatedphase_2

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368

Clinical Trials (5)

Showing 5 of 5 trials
NCT06639854Not Applicable

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Recruiting
NCT05907746Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Active Not Recruiting
NCT02766465Phase 2

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed
NCT02639559Phase 2

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
NCT01343368Phase 2

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Terminated

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5